The world’s first oral treatment for AMD.
We are bringing your eyes back to their youthfulness.The MHRA in the United Kingdom has approved a Clinical Trial Authorization (CTA) for an oral treatment for Age-related Macular Degeneration (AMD) to proceed to a Phase 2b clinical trial.
AltRegen
is a biomedical company dedicated to developing a treatment for
AMD and specializes in the biophysical aspects of Bruch’s
membrane of the eye. We are working with numerous
internationally respected world experts on AMD.
Our research elucidated the underlying mechanisms in AMD
allowing us to formulate a treatment for this disease. As a
consequence, we now hold
worldwide patents and formulations for the prevention and
treatment of AMD.
This is the only company to have developed a formula for
removing the age-related accumulation of debris from Bruch’s
membrane.AltRegen® formulation improves transport across Bruch’s
membrane to restore the deficits in dark adaptation occurring in
elderly people and AMD patients.
This means that the AltRegen® formulation improves the structure
and function of Bruch’s membrane enabling the maintenance of
good vision. Our teams have worked on this important project for
many years and
will not give up until we establish a treatment to help the
patients.
We are happy to give you the
opportunity to maintain good vision and prevent blindness
allowing you a better quality of life.
We will help to maintain your eyesight to enjoy life with your loved ones.
Learn more about AMD
Everything you need to know about Age-related Macular Degeneration.